Global Allergy Immunotherapies Market 2016-2020

  • ID: 3776028
  • Report
  • Region: Global
  • 87 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Adamis Pharmaceuticals
  • Allergy Therapeutics
  • Biomay
  • Genentech
  • Merck Group
  • Sementis
  • MORE
About the Allergy Immunotherapies Market

Immunotherapy, often referred to as desensitization, is the closest thing to a cure for allergic diseases and is an established treatment for severe allergies such as allergic rhinitis and allergic asthma. Its administration includes increasing the doses of allergen extracts over a span of time either through injections or sublingual tablets and drops.

Allergies occur when a foreign substance, which is mostly harmless, reacts with the immune system. These foreign substances are called allergens. Some allergens that affect the immune system are animal dander, dust mite, pollens, cockroach, and mold. Animal dander, dust mite, and mold cause indoor allergies.

There are various types of allergies, including rhinitis, asthma, eye allergy, and skin allergy. Sometimes, severe allergies can lead to death, as the severity of these allergic reactions interfere with the proper function of organs. For instance, allergic rhinitis and asthma cause the lungs to function poorly.

The analysts forecast the global allergy immunotherapies market to grow at a CAGR of 7.3% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global allergy immunotherapies market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat allergic diseases such as allergic rhinitis and allergic asthma. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
- Europe
- North America
- ROW

The report, Global Allergy Immunotherapies Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- ALK-Abello
- Stallergenes
- Merck Group
- Allergy Therapeutics

Other prominent vendors
- Adamis Pharmaceuticals
- Aimmune Therapeutics
- Anergis
- ASIT biotech
- Biomay
- Circassia
- DBV Technologies
- Genentech
- HAL Allergy
- Laboratorios LETI
- Mitsubishi Tanabe Pharma
- Nycomed
- Sementis
- Shionogi
- Torii
- Tunitas Therapeutics
- VentiRx Pharmaceuticals
- Verona Pharma

Market drivers
- Presence of high unmet medical needs
- For a full, detailed list, view the full report

Market challenges
- Poor patient adherence and high dropout rates
- For a full, detailed list, view the full report

Market trends
- Advent of SPIRE
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Adamis Pharmaceuticals
  • Allergy Therapeutics
  • Biomay
  • Genentech
  • Merck Group
  • Sementis
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market Overview
  • Assumptions
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Allergies: Overview
  • Prevalence of allergic diseases
PART 06: Pipeline analysis

PART 07: Market landscape
  • Market overview
  • Five forces analysis
PART 08: Market segmentation by product type
  • Global SCIT market
  • Global SLITD market
  • Global SLITT market
PART 09: Geographical segmentation
  • Allergy immunotherapies market in Europe
  • Allergy immunotherapies market in Germany
  • Allergy immunotherapies market in France
  • Allergy immunotherapies market in North America
  • Allergy immunotherapies market in US
  • Allergy immunotherapies market in ROW
PART 10: Market drivers
  • Presence of high unmet medical needs
  • Existence of novel molecules in pipeline
  • Increasing prevalence of allergic rhinitis and asthma coupled with high consumption of tobacco
  • Upsurge of allergies due to increase in environmental pollution
PART 11: Impact of drivers

PART 12: Market challenges
  • Increased preference for CAM
  • Poor patient adherence and high dropout rates
  • High cost of allergic immunotherapy
PART 13: Impact of drivers and challenges

PART 14: Market trends
  • Emergence of SLITT
  • Advent of SPIRE
  • Strategic alliances for novel drug developments
  • Identification of new allergen targets
PART 15: Vendor landscape
  • Competitive scenario
  • ALK-Abello
  • Stallergenes
  • Merck Group
  • Allergy Therapeutics
  • Other prominent vendors
PART 16: Appendix
  • List of abbreviations
PART 17: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Impact of key customer segments 2015
Exhibit 03: Prevalence of HDM allergies in major countries 2015
Exhibit 04: Incidence of allergies 1920-2020 (% of population)
Exhibit 05: Prevalence of allergies in US 2015
Exhibit 06: Prevalence of allergies in Europe 2015
Exhibit 07: Global allergy immunotherapies market: Pipeline portfolio
Exhibit 08: Global allergy immunotherapies market according to drug phase 2015
Exhibit 09: Major pipeline events for allergy immunotherapies 2016-2017
Exhibit 10: Global allergy immunotherapies market snapshot: Developed and emerging markets 2015
Exhibit 11: Growth opportunities for global allergy immunotherapies market
Exhibit 12: Global allergy immunotherapies market 2015-2020 ($ billions)
Exhibit 13: Comparison of active ingredients used in allergy immunotherapy
Exhibit 14: Major healthcare reforms in global allergy immunotherapies market
Exhibit 15: Five forces analysis
Exhibit 16: Global allergy immunotherapy market segmentation by product type 2015
Exhibit 17: Advantages of short-course SCITs
Exhibit 18: Opportunity analysis of global SCIT market
Exhibit 19: Global SCIT market 2015-2020 ($ millions)
Exhibit 20: Opportunity analysis of global SLITD market
Exhibit 21: Global SLITD market 2015-2020 ($ millions)
Exhibit 22: Opportunity analysis of global SLITT market
Exhibit 23: Global SLITT market 2015-2020 ($ millions)
Exhibit 24: Comparison between whole allergen immunotherapies, SCIT, and SLIT
Exhibit 25: Global allergy immunotherapies market segmentation by product type 2015-2020 ($ millions)
Exhibit 26: Global allergy immunotherapies market segmentation by product type 2015-2020
Exhibit 27: Global allergy immunotherapies market: YoY revenue and growth based on product type 2015-2020 ($ millions)
Exhibit 28: Global allergy immunotherapies market: Geography outlook (2015-2020)
Exhibit 29: Revenue and growth outlook in different countries 2015
Exhibit 30: Global allergy immunotherapies market by geographical segmentation 2015
Exhibit 31: Allergy immunotherapies market in Europe 2015-2020 ($ millions)
Exhibit 32: Market share of SLITT and SCIT/SLITD in Europe 2015
Exhibit 33: Market share of allergy immunotherapies in Europe
Exhibit 34: Allergy immunotherapies market in Germany 2015-2020 ($ millions)
Exhibit 35: Allergy immunotherapies market in France 2015-2020 ($ millions)
Exhibit 36: Allergy immunotherapies market in North America 2015-2020 ($ millions)
Exhibit 37: Market share of SLITT and SCIT/SLITD in North America 2015
Exhibit 38: Allery immunotherapies market in North America
Exhibit 39: Market share of allergy immunotherapies in North Americas
Exhibit 40: Allergy immunotherapies market in US 2015-2020 ($ millions)
Exhibit 41: Allergy immunotherapies market in ROW 2015-2020 ($ millions)
Exhibit 42: Global allergy immunotherapies market revenue by geography 2015-2020 ($ millions)
Exhibit 43: Global allergy immunotherapies market revenue by geography 2015-2020
Exhibit 44: Global allergy immunotherapies market: YoY revenue and growth based on geography 2015-2020 ($ millions)
Exhibit 45: Unmet medical needs for severely affected individuals: Key allergens and severe allergic cases
Exhibit 46: Impact of drivers
Exhibit 47: Use of CAM therapies among individuals in US
Exhibit 48: Comparison of different cost components of allergy immunotherapy ($) 2014
Exhibit 49: Impact of drivers and challenges
Exhibit 50: Advantages of SPIRE allergy therapies
Exhibit 51: Market share analysis
Exhibit 52: Market position of top vendors 2015
Exhibit 53: Competitive position of vendors
Exhibit 54: Key vendors: Geographical presence 2015
Exhibit 55: Market share analysis in US
Exhibit 56: Market share analysis in Europe
Exhibit 57: Business segmentation by revenue 2015
Exhibit 58: ALK-Abello: YoY revenue and growth rate of SCIT/SLIT drops 2013-2015 ($ millions)
Exhibit 59: Geographic segmentation of SCIT/SLIT drops 2015
Exhibit 60: ALK-Abello: YoY revenue and growth rate of SLIT tablets 2013-2015 ($ millions)
Exhibit 61: ALK-Abello: Geographic segmentation of SLIT tablets 2015
Exhibit 62: ALK-Abello: Metrics analysis
Exhibit 63: Product categories by revenue
Exhibit 64: Stallergenes: Geographical segmentation by revenue 2015
Exhibit 65: Stallergenes: Metrics analysis
Exhibit 66: Allergopharma: YoY revenue and growth rate of allergy immunotherapy products 2013-2015 ($ millions)
Exhibit 67: Merck Group: Metrics analysis
Exhibit 68: Allergy Therapeutics: YoY revenue and growth rate of key allergy immunotherapies 2013-2015 ($ millions)
Exhibit 69: Allergy Therapeutics: Products by revenue 2015
Exhibit 70: Allergy Therapeutics: Geographical segmentation by revenue 2015
Exhibit 71: Allergy Therapeutics: Metrics analysis
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Adamis Pharmaceuticals
  • Allergy Therapeutics
  • Biomay
  • Genentech
  • Merck Group
  • Sementis
  • MORE
New Report Released: – Global Allergy Immunotherapies Market 2016-2020

The author of the report recognizes the following companies as the key players in the global allergy immunotherapies market: ALK-Abello, Stallergenes, Merck Group, and Allergy Therapeutics.

Other Prominent Vendors in the market are: Adamis Pharmaceuticals, Aimmune Therapeutics, Anergis, ASIT biotech, Biomay, Circassia, DBV Technologies, Genentech, HAL Allergy, Laboratorios LETI, Mitsubishi Tanabe Pharma, Nycomed, Sementis, Shionogi, Torii, Tunitas Therapeutics, VentiRx Pharmaceuticals, and Verona Pharma.

Commenting on the report, an analyst from the research team said: “A trend propelling market growth is the advent of SPIRE. The SPIRE allergy immunotherapy is a novel method to treat allergies. This therapy uses the proprietary MicronJet system to maximize the immune response. MicronJet, a novel device approved in the US and the EU, provides patient friendly, consistent, and intradermal administration of drugs. Vendors are showing an interest in this patented novel synthetic pharmaceutical technology due to its ease of use and compatibility compared to the complex techniques of existing immunotherapies.”

According to the report, a key growth driver is the presence of high unmet medical needs. Though existing therapies are highly effective in relieving and controlling symptoms, the market still requires drugs that reduce inflammation and irreversible airway remodeling. In Europe, the US, and Japan, an estimated 39 million individuals are not in control of their respiratory-related allergies, as only a few drugs provide appropriate treatment; only about 4.5 million receive AIT. Globally, only 55% of all the allergic rhinitis cases have been diagnosed. In addition, allergic rhinitis and allergic asthma are chronic diseases that cannot be cured, and most patients needed lifelong treatment and lifestyle adjustments. Thus, an unmet medical need exists for novel targeted drugs that treat the underlying cause of these conditions.

Further, the report states that one challenge that could hamper market growth is poor patient adherence and high dropout rates from treatment programs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- ALK-Abello
- Stallergenes
- Merck Group
- Allergy Therapeutics
- Adamis Pharmaceuticals
- Aimmune Therapeutics
- Anergis
- ASIT biotech
- Biomay
- Circassia
- DBV Technologies
- Genentech
- HAL Allergy
- Laboratorios LETI
- Mitsubishi Tanabe Pharma
- Nycomed
- Sementis
- Shionogi
- Torii
- Tunitas Therapeutics
- VentiRx Pharmaceuticals
- Verona Pharma
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll